COVID-19
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 12, 2020.
Novavax secured the funding from the Coalition for Epidemic Preparedness Innovations to further develop the vaccine candidate as well as support a rapid scale-up of manufacturing to support the vaccine, should it prove to be effective.
A smartphone diagnostic test for COVID-19 being developed by a University of Utah researcher holds the potential for quick, accurate testing without the need for individuals to go to a healthcare facility. A prototype may be ready within two to three months.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
The new at-home saliva self-collection assay allows for broader screening than the standard and uncomfortable method using nose and throat swabs at a healthcare facility or testing location that requires a physical interaction with a healthcare professional.
A study published by researchers from The Mount Sinai Hospital/Mount Sinai School of Medicine on May 6 revealed that blood thinners may slow down clotting in patients with COVID-19, ultimately improving their chances of survival.
One day after Moderna announced its COVID-19 vaccine candidate has moved into Phase II testing, Chief Executive Officer Stéphane Bancel laid out the bad news – if it works, there won’t be enough of the vaccine to be quickly distributed across the globe.
The research was published in the New England Journal of Medicine on Thursday, May 7.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
PRESS RELEASES